Previous Close | 0.0700 |
Open | 0.0700 |
Bid | 0.0000 |
Ask | 0.7500 |
Strike | 35.00 |
Expire Date | 2024-10-18 |
Day's Range | 0.0700 - 0.0700 |
Contract Range | N/A |
Volume | |
Open Interest | 14 |
WATERTOWN, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an
- Appointment strengthens leadership team as Company approaches dosing of patients in Phase 3 pivotal trials of DURAVYU™ in wet AMD in 2024 -WATERTOWN, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Fred Hassan, a distinguished industry leader to its Board of Directors. “I am hono
WATERTOWN, Mass., Aug. 27, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced that company management will participate at the following upcoming conferences: Morgan Stanley Annual Global Healthcare ConferenceForum: 1x1 Investor MeetingsDate: Wednesday, September 4, 2024 Baird Global Healthcare ConferenceForum: Fireside